The Influence of Acute Moderate-intensity Continuous Exercise on Appetite Regulation
Lead sponsor
Asset
GLP-1 / incretin class catch-all
Listed sites
1
Recruiting sites
-
Actual enrollment
20
Study population
Healthy volunteers
Eligibility highlights
•BMI 18.5-24.9
Primary endpoints
•Oxyntomodulin•Growth Differentiation Factor 15
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (4)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Patient-reported / QoL
1 endpointVisual analogue score (VAS) for subjective appetite
Time frame:VAS was measured at 0 (baseline), 60, 90, 120, 150, 180, 210 minutes in each trial.
change from baseline, improvement
Other (unclassified)
3 endpointsOxyntomodulin
Time frame:Blood samples were collected for oxyntomodulin measurements at 0 (baseline), 60, 90, 120, 150, 180, 210 minutes in each trial.
concentration, descriptive
Growth Differentiation Factor 15
Time frame:Blood samples were collected for GDF-15 measurements at 0 (baseline), 60, 90, 120, 150, 180, 210 minutes in each trial.
concentration, descriptive
Energy intake
Time frame:Ad libitum pasta meal provided at 120 minutes.
descriptive
Publications (1)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- Appetite2026 Jul 1PMID41833829doi:10.1016/j.appet.2026.108541via clinicaltrials gov reference derived + pubmed nct search
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.